The National Cancer Institute (NCI) shared on LinkedIn:
“Press Release:
New results from an NCI clinical trial – the first to evaluate the drug invikafusp alfa (invika) in humans – indicate that the pioneering treatment may be capable of managing cancers that have rebuffed most other treatments, including standard immunotherapy.
The study found that, at optimal doses, invika was well tolerated and, in patients whose cancers had resisted standard immunotherapy, halted disease progression in most and shrank tumors in some.
Other articles about The National Cancer Institute on OncoDaily.